| Full text | |
| Author(s): |
Mauricio, Adriana Fogagnolo
[1]
;
de Carvalho, Samara Camacari
[1]
;
Santo Neto, Humberto
[1]
;
Marques, Maria Julia
[1]
Total Authors: 4
|
| Affiliation: | [1] Univ Estadual Campinas, UNICAMP, Dept Struct & Funct Biol, Inst Biol, BR-13083970 Campinas, SP - Brazil
Total Affiliations: 1
|
| Document type: | Journal article |
| Source: | CLINICAL NUTRITION ESPEN; v. 20, p. 60-67, AUG 2017. |
| Web of Science Citations: | 2 |
| Abstract | |
Background \& aims: Duchenne muscular dystrophy (DMD) is characterized by the absence of dystrophin and muscle degeneration. Calcium dysregulation and oxidative stress also contribute to the disease progression. We evaluated the potential therapeutic benefits of supplementation with omega-3 on the metabolic profile, calcium-related proteins and oxidative stress response in the heart and diaphragm (DIA) of the mdx mouse model of DMD at later stages of the disease (13 months). Methods: Mdx mice (8 months old) received omega-3 via a dietary supplement for 5 months. Metabolites were analyzed by H-1 magnetic resonance spectroscopy. Muscle total calcium was evaluated by inductively coupled plasma-optical emission spectrometry. Calsequestrin, TRPC1 and 4-HNE were determined via Western blot. Results: Omega-3 decreased the metabolites taurine (related to calcium regulation and oxidative stress), aspartate (related to inflammation) and oxypurinol (related to oxidative stress) in the heart (aspartate) and DIA (taurine, aspartate and oxypurinol). Omega-3 also significantly decreased total calcium and TRPC1 levels in cardiac and DIA muscles and increased the levels of calsequestrin (cardiac and skeletal) and decreased the oxidative stress marker 4-HNE. Conclusions: The current study suggests that supplementation with omega-3 may generate therapeutic benefits on dystrophy progression, at later stages of the disease, with changes in the metabolic profile that may be correlated to omega-3 therapy. (C) 2017 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved. (AU) | |
| FAPESP's process: | 08/58491-1 - Mecanismos de proteção da distrofia muscular: estudo proteômico e terapia farmacológica |
| Grantee: | Maria Julia Marques |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 11/51697-6 - Mecanismos de acao do acido eicosapentanoico (epa) na protecao a mionecrose em fibras musculares distroficas |
| Grantee: | Maria Julia Marques |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 12/13577-1 - Biomarkers of cardiomyopathy in dystrophy: a metabolomic study and pharmacological therapy |
| Grantee: | Adriana Fogagnolo Mauricio |
| Support Opportunities: | Scholarships in Brazil - Doctorate |
| FAPESP's process: | 12/15492-3 - Pharmacological therapy of the dystrophinopathies: fibrosis and muscular regeneration in mdx mice treated with omega-3 |
| Grantee: | Samara Camaçarí de Carvalho |
| Support Opportunities: | Scholarships in Brazil - Doctorate |
| FAPESP's process: | 14/04782-6 - Pre-clinical studies in the mdx mouse: metabolomics, biomarkers and omega-3 therapy |
| Grantee: | Maria Julia Marques |
| Support Opportunities: | Regular Research Grants |